VolitionRx appoints industry veterans Kim Nguyen and Richard Brudnick to its board of directors

VolitionRx Limited (NYSEAMERICAN:VNRX) announced the appointments of Kim Nguyen and Richard Brudnick to the company's board of directors effective March 25.  Nguyen is an international Human Resources (HR) professional with over 20 years of experience working with fast-growing, multinational technology companies and is currently serving as Head of HR for Google Asia Pacific Pte. Ltd, while Brudnick has held senior positions in a number of pharmaceutical companies and currently serves as Chief Business Officer and Head of Corporate Strategy of Codiak BioSciences, Inc.  “We are pleased to welcome Kim and Richard to the Volition Board of Directors to help the company transition into the commercialisation phase, with anticipated product launches worldwide,” VolitionRx Executive Chairman Dr. Martin Faulkes said in a statement. READ: VolitionRx’s Nu.Q cancer-screening blood tests could replace colonoscopies, biopsies “Both directors join in an independent capacity and bring with them extensive business experience, in particular, Kim with global HR expertise and Richard with extensive commercialisation know-how and, as such, will provide valuable strategic, operational and commercial management input to our Board,” Dr. Faulkes added. Nguyen also commented, stating: “I am delighted to join the Volition team at such an exciting time. Volition's employees and consultants have been at the very heart of the company's achievements to-date and I look forward to help shaping Volition's future organisational strategy.” Brudnick added: “I too am excited to join Volition as it embarks on the commercialisation of its Nu.Q technology platform. This simple, cost-effective ELISA platform could provide an accessible test to millions of people around the world.” The company noted that Nguyen was also appointed as Chair of its Compensation Committee and as a member of the Nominations and Governance Committee, while Brudnick was appointed as a member of VolitionRx's Audit Committee and Compensation Committee. VolitionRx is an epigenetics company that develops easy-to-use blood-based tests to accurately diagnose a range of cancers. The company has designed a routine test called Nu.Q to screen for blood, colorectal, lung, and prostate cancers that reduces the need for more invasive colonoscopies and biopsies. VolitionRx also is advancing plans to develop Nu.Q as a method to monitor the treatment of sepsis.  Contact Sean at sean@proactiveinvestors.com